ABSTRACT The efficacy of twice daily inhaled beclomethasone dipropionate administered by a concentrated aerosol inhaler (one puff twice daily-500 pg/day) has been compared with that of treatment four times daily with a standard dose inhaler (two puffs four times daily-400 Mg/day) in 21 patients with stable asthma. Double placebo inhalers were used in a randomised crossover fashion during two four week treatment periods. Mean peak expiratory flow (PEF), mean symptom scores, and number of extra salbutamol inhalations required were not significantly different between the two treatment periods. Local side effects were more common during treatment with the four times daily active preparation; overt oropharyngeal candidiasis, however, was not found in either group during the study. On completion of the crossover study patients were transferred to the twice daily regimen. At the three month follow up all patients had remained stable and the outpatient PEF was significantly higher (mean 382 (SD 26)1min-1) than at entry into the trial (mean 345 (24)1 min-1) (p < 0O05). Twice daily beclomethasone administered by a concentrated aerosol inhaler appears to be as effective as the standard four times daily regimen in controlling stable asthma. Accepted 18 May 1986 inhalations a day from the standard 50 pg inhaler (two puffs four times daily-400 pg) with two inhalations a day (one puff twice daily-500 pg) from the concentrated inhaler.
The mode of action of inhaled corticosteroids in providing prophylaxis in asthma requires them to Accepted 18 May 1986 inhalations a day from the standard 50 pg inhaler (two puffs four times daily-400 pg) with two inhalations a day (one puff twice daily-500 pg) from the concentrated inhaler.
Methods
To enter the study patients were required to have asthma, with at least 20% reversibility in peak expiratory flow (PEF) Patients recorded PEF (best of three blows) four times daily throughout the trial before using their inhalers. In addition, they were asked to fill in diary cards twice daily. Outpatient clinic assessments were made on days 0, 28, and 56 and included measurement of PEF, FEV1, and forced vital capacity (FVC) . Patients were questioned about side effects, the oropharynx was inspected, and swabs were taken from each patient on days 28 and 56.
On completion of the crossover study, if there had been no obvious deterioration in asthma control the patients were asked to take one puff twice daily of a concentrated inhaler preparation (Becloforte) instead of using their original 50pg metered dose inhaler.
They were then reviewed in the clinic after three months to assess their progress. For overall comparisons between the two treatment periods, diary card recordings from the last three weeks of each period were included, weeks one and five of the study being excluded to avoid residual effects from the previous period. For comparisons within each treatment period, however, weeks one and five were included. Paired t tests were used to make comparisons between the treatment periods.
Results
Twenty three patients entered the study but two were subsequently excluded because of lack of cooperation. The remaining 21 patients, 10 men and 11 women, completed the study satisfactorily. Their mean age was 501 (range 23-72) years. Eighteen of the patients were atopic as defined by positive responses to skinprick tests with common allergens, and three were not. Eleven patients received the four times daily active regimen first and 10 patients the twice daily active regimen first.
Mean PEF readings for the two treatment periods were similar at all times of the day (figure). Mean values were slightly higher during the four times daily active period but not significantly so. Similarly symptom scores and number of extra salbutamol inhalations were not significantly different for the two treatment periods. Outpatient PEF recordings before salbutamol inhalation tended to be higher at the end of both the four times daily active period ( (SD 32)1 min-1) and the twice daily active period (357 (31)1min-1) than at entry into the trial (mean 329 (22)1 min-1), but the differences were not significant. Nine patients (43%) had a rise of at least 20% in 6 am PEF during the course of the trial, which was then sustained. In five patients this occurred during the first four weeks of the trial and in one during the second four weeks, and in three there was a continued improvement during both periods. Improvement was seen with similar frequency in the two treatment groups. A similar increase in 6 pm PEF was seen in five patients (24%). In the remaining 12 patients changes in mean daily PEF values were variable; no patient, however, showed significant deterioration in PEF during the trial with either treatment regimen.
No patient had evidence of oropharyngeal candidiasis on clinical examination during the study. During the four times daily active regimen three patients complained of some intermittent soreness or dryness of the mouth, three more complained of intermittent huskiness of the voice, and one patient experienced both of these symptoms. During the twice daily active regimen only one patient complained of slight sore-I 961 962 ness in the throat and none of hoarseness. Positive swab cultures for Candida albicans were found in three patients; in two the culture growth was moderate and in the other scanty. All occurred during the twice daily active period. None of these three patients, however, had experienced any symptoms in the mouth or throat.
Eighteen of the 21 patients attended for review three months after finishing the study. Fourteen had continued with one puff twice daily of the concentrated inhaler preparation (500 pg/day) and all of these patients continued to have their asthma well controlled with no acute exacerbations. Peak flow measured at the three month follow up visit was significantly higher (mean 382(SD26)1min-') than at entry into the trial (mean 345 (24)1min-1) (p < 005) and was similar to that at the end of the twice daily active period (mean 384 (42)1 min-') and the four times daily active period (mean 376 (42)1 min 1). 9 In support of this, symptoms of sore mouth and dysphonia occurred more frequently with the four times daily active regimen in this study; no patient, however, required treatment for these. In agreement with other studies,'0 there appeared to be no relationship between the finding of a positive swab culture for candidiasis and the occurrence of local symptoms.
In conclusion, inhalation of steroids by means of a concentrated aerosol inhaler twice daily is as effective in the maintenance treatment of stable asthma as a similar dose administered with a conventional dose inhaler four times daily. The advantages of this regimen are convenience to the patient, fewer local side effects and, in some patients, improved compliance with even better control of the asthma.
